Novel Insulin Offers Similar Results as Lantus

June 15, 2014 1:55 PM

530 0

SAN FRANCISCO -- A new insulin glargine product proved to be noninferior to the top-selling Lantus in patients with type 1 and type 2 diabetes, researchers reported here.

The new insulin glargine (LY2963016) being developed by Eli Lilly and Boehringer Ingelheim showed similar reductions in HbA1c and hypoglycemia as Lantus in both types of diabetes patients, researchers reported here in three oral presentations of data from the ELEMENT series of trials.

Read more

To category page